About IMI




On 18–19 February, 2016, we celebrated the successful completion of the Open PHACTS project with a conference on linking life science data in Vienna, Austria.

79 attendees from a broad cross-section of backgrounds gathered to discuss what lessons have been learned from the success of Open PHACTS, and how the Open PHACTS Foundation will take the project’s outcomes forward.



A long-time partner of the Open PHACTS project, the University of Vienna has committed to supporting the Open PHACTS Foundation as our first academic member. Professor Gerhard Ecker and his colleagues bring a wealth of expertise and experience in linked pharmacological data to the Foundation, and we are excited about working together to continue building on the achievements of Open PHACTS.




  • API 2.0 is here
  • Decommissioning API 1.4
  • Upcoming conference: Linking Life Science Data
  • New Foundation member: University of Vienna


We’re excited to announce the official release of version 2.0 of the Open PHACTS API, along with major updates to the linked data in the Open PHACTS Discovery Platform.

Try out API version 2.0 now



There are just three weeks to go until our conference, Linking Life Science Data: From Design to Implementation, and Beyond. If you haven’t yet registered, attendance is free and there are still places available:

Register now


The Open PHACTS project is supported by the Innovative Medicines Initiative (IMI), a large-scale public-private partnership between the European Union and the pharmaceutical industry association EFPIA.

IMI aims to boost biopharmaceutical innovation in Europe and to speed up the development of better and safer medicines for patients. Through its unique and innovative funding scheme, IMI supports research projects in the areas of safety and efficacy, knowledge management and education and training.

In addition to the large biopharmaceutical companies, the participating research consortia include small- and medium-sized enterprises, patient organisations, academia and other research organisations, hospitals and public authorities.

The European Commission's Seventh Framework Programme contributes €1 billion to the IMI research programme. That amount is matched by in kind contributions worth at least another €1 billion from the pharmaceutical companies that are members of EFPIA, the European Federation of Pharmaceutical Industries and Associations.

Find out more: www.imi.europa.eu

Useful links